Skip to main content
Fig. 3 | Orphanet Journal of Rare Diseases

Fig. 3

From: Sebelipase alfa enzyme replacement therapy in Wolman disease: a nationwide cohort with up to ten years of follow-up

Fig. 3

Long-term follow-up of growth parameters in five Wolman disease (WD) patients treated with sebelipase alfa. A Weight, B height, C head circumference and D body mass index (BMI) expressed in standard deviations and measured in Patients 1–5 (P#1–P#5), before (black) and under (orange) enzyme replacement therapy (ERT). BMI growth curves start at 2 years explaining the absence of values in P#5 and before treatment. Median ± interquartile range

Back to article page

Orphanet Journal of Rare Diseases

ISSN: 1750-1172